Key statistics
On Wednesday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 9.29, 42.70% above the 52 week low of 6.51 set on Apr 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.13 |
---|---|
High | 9.44 |
Low | 8.91 |
Bid | 6.50 |
Offer | 9.41 |
Previous close | 9.48 |
Average volume | 26.41k |
---|---|
Shares outstanding | 1.54m |
Free float | 1.48m |
P/E (TTM) | -- |
Market cap | 13.85m USD |
EPS (TTM) | -8.05 USD |
Data delayed at least 15 minutes, as of Jul 09 2025 20:54 BST.
More ▼
Announcements
- Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
- Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
- Addex Convenes Annual General Meeting 2025
- Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
- Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
- Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
More ▼